Table 3.
Economic evaluation of antimicrobial central venous catheters: incremental costs and health outcomes under baseline analysis
| Catheter type | Infections avoideda | ICU bed days releaseda | Costs saveda (2006 AUD) | QALYs gaineda | ICER | Average monetary net benefitsb (95% confidence interval) |
| Uncoated | 390,664 (371,984 to 408,416) | |||||
| CH/SSD (ext) | 8.4 | 18.1 | $93,281 | 0.91 | Dominated | 391,212 (372,736 to 408,687) |
| CH/SSD (int/ext) | 7.4 | 15.9 | $51,126 | 0.80 | Dominated | 391,030 (372,467 to 408,574) |
| SPC | 11.4 | 24.6 | $120,062 | 1.23 | Dominated | 391,206 (372,687 to 408,772) |
| MR | 15.2 | 32.8 | $130,289 | 1.64 | Cost-saving | 391,612 (373,159 to 408,861) |
aResults presented per 1,000 catheters; bMonetary net benefits reported per catheter assuming a willingness-to-pay for a QALY of AUD $40,000.
CH/SSD, chlorhexidine silver sulfadiazine; ICER, incremental cost effectiveness ratio; ICU, intensive care unit; int/ext, internally and externally coated; QALY, quality-adjusted life year; MR, minocycline and rifampicin; SPC, silver, platinum and carbon.